Association of PD-1 and PDL-1 gene polymorphisms with colorectal cancer risk and prognosis.

Autor: Cevik M; Department of Molecular Biology, Marmara University Faculty of Arts and Science, Istanbul, Turkey., Namal E; Department of Medical Oncology, Demiroglu Bilim University Faculty of Medicine, Istanbul, Turkey., Iner-Koksal U; Istanbul Bagcilar Training and Research Hospital, Istanbul, Turkey., Dinc-Sener N; Department of Medical Oncology, Demiroglu Bilim University Faculty of Medicine, Istanbul, Turkey., Karaalp A; Department of Medical Pharmacology, Marmara University School of Medicine, Istanbul, Turkey., Ciftci C; Department of Cardiology, Demiroglu Bilim University Faculty of Medicine, Istanbul, Turkey., Susleyici B; Department of Molecular Biology, Marmara University Faculty of Arts and Science, Istanbul, Turkey. belginsusleyici@gmail.com.
Jazyk: angličtina
Zdroj: Molecular biology reports [Mol Biol Rep] 2022 Mar; Vol. 49 (3), pp. 1827-1836. Date of Electronic Publication: 2022 Jan 25.
DOI: 10.1007/s11033-021-06992-9
Abstrakt: Background: Programmed Cell Death-1 (PD-1) together with Programmed Death Ligand 1 (PDL-1) have crucial roles in anti-tumor immune response, cancer susceptibility and prognosis. Since PD-1 and PDL-1 have been considered as important genetic risk factors in cancer development and their functions can be affected by polymorphic sites, we investigated the effects of PD-1 rs2227981, rs2227982, rs36084323 and PDL-1 rs2282055, rs822336 gene polymorphisms on colorectal cancer (CRC) risk and prognosis in Turkish subjects.
Methods and Results: Our study group consisted of 5-FU or Capacitabine prescribed CRC diagnosed patients and healthy controls. Genotype analyses of PD1 and PDL-1 polymorphisms were performed with Agena MassARRAY platform. rs36084323 CT genotype frequency was found to be higher in controls compared to cases (p < 0.001). rs36084323 CT genotype was highly associated with reduced CRC risk compared to CC genotype (OR 0.068, 95% CI 0.022-0.211, p < 0.001). In adjusted analysis, rs2282055 GG genotype was found to be associated with reduced CRC risk (OR 0.271, 95% CI 0.078-0.940, p = 0.040). rs2282055 TT genotype was found to be related to longer progression-free (Bonferroni corrected Log rank p = 0.013) and overall survival (Bonferroni corrected Log rank p = 0.009) to that of GG genotypes. Patients with rs822336 GC+CC genotypes showed longer overall survival times compared to GG (Log rank p = 0.044).
Conclusions: According to our results, PD-1 rs822336 G > C polymorphism might be useful in predicting CRC prognosis. PDL-1 rs2282055 T > G polymorphism might be useful in predicting both CRC risk and prognosis. Further studies should be conducted in larger and different populations to clear the roles of PD-1 and PDL-1 polymorphisms in CRC risk and prognosis.
(© 2022. The Author(s), under exclusive licence to Springer Nature B.V.)
Databáze: MEDLINE
Externí odkaz: